Von Hippel-Lindau Disease Market Insights, Diagnosis and Treatment Market by DelveInsight

Von Hippel-Lindau Disease Market Insights, Diagnosis and Treatment Market by DelveInsight

The Von Hippel-Lindau Disease Market report provides current treatment practices, emerging drugs, Von Hippel-Lindau (VHL) Disease market share of the individual therapies, current and forecasted Von Hippel-Lindau (VHL) Disease market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Von Hippel-Lindau (VHL) Disease diagnostic criteria, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Von Hippel-Lindau Disease Overview

Von Hippel–Lindau (VHL) disease is an autosomal dominantly inherited disorder that demonstrates marked phenotypic variability and age-dependent penetrance. A germline mutation in the VHL gene predisposes carriers to the development of abundantly vascularized tumors in multiple organs.

 

Request free sample copy- https://www.delveinsight.com/sample-request/von-hippel-lindau-disease-market

 

List of regions covered in the report-

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

List of companies involved in the report-

  • Peloton Therapeutics (acquired by Merck)
  • Novartis
  • And many others

 

Von Hippel-Lindau Disease Symptoms

The most common symptom of VHL is hemangioblastomas. CNS hemangioblastomas are among the most common manifestations of VHL disease. Other than this, VHL clinical manifestations also include, Renal Cell Carcinomas (RCC), Renal Cysts, Pheochromocytoma, Retinal hemangioblastomas, Papillary cystadenomas of the broad ligament, Cystadenomasin the epididymis, Pancreatic Neuroendocrine Tumors and Cysts, and Endolymphatic sac tumors (ELSTs).

 

Von Hippel-Lindau Disease Diagnosis

Diagnostic tests include, initial screening workup including a thorough history and clinical examination, an ophthalmologic examination including fundoscopy, MR imaging of the craniospinal axis, kidneys, pancreas, and liver, an audiological examination, and laboratory tests (to detect pheochromocytomas). Genetic testing of the peripheral leukocytes and/or other body tissues is performed to confirm the presence of a VHL gene mutation.

 

Von Hippel-Lindau Disease Treatment Market

Treatment for VHL disease depends on the location and size of tumors. In general, the goal is to treat growths when they cause symptoms but are still small, so they do not cause permanent damage. Although there is no cure for VHL, the associated tumors can be treated. Treatment usually involves surgical removal of tumors. Radiation therapy may be used in some cases. Early detection and treatment of tumors significantly improve a patient’s diagnosis. Systemic treatment is recommended in the metastatic setting, addressing the same therapeutic principles as in sporadic malignancies. Due to the rarity of VHL, data on systemic treatment is sparse. VEGF-targeting agents seem to be a reasonable choice with regard to pathophysiology in most tumors.

 

Von Hippel-Lindau Disease Market Insights

VHL disease is caused by a flaw in one gene, the VHL gene, which regulates cell growth. This flaw, for which the cause is unknown, leads to the abnormal growth of blood vessels in certain parts of the body. Instead of growing and spreading out normally (like a tree), in patients with VHL, the blood vessels grow into clumps.

 

Von Hippel-Lindau Disease Emerging Drugs

  • Belzutifan/MK 6482 (Merck)
  • DFF332 (Novartis)
  • And many others

 

Von Hippel-Lindau Disease Market Report Highlights

  • Increase in VHL market size is anticipated for the study period, 2018–2030 with a CAGR of 8.3%.
  • VHL market is expected to grow significantly owing to an increase in upcoming novel treatment options and their expansion in to the other tumor types as well, rapid advancements in molecular diagnostics in VHL and increasing awareness of VHL disease. Several organizations such as VHL Alliance aim to create awareness and ongoing research to focus on the genetic factor of VHL disease.

 

Request free sample copy- https://www.delveinsight.com/sample-request/von-hippel-lindau-disease-market

 

Table of Content

1. Key Insights

2. Report Introduction

3. Von Hippel-Lindau (VHL) disease Market Overview at a Glance

4. Executive Summary of Von Hippel-Lindau (VHL) disease

5. Epidemiology and Market Methodology

6. Disease Background and Overview

7. Diagnosis of VHL

8. Diagnostic Guidelines

9. Current Treatment Practices of VHL

10. Treatment Guidelines

11. Epidemiology and Patient Population

12. Patient Journey

13. Key Endpoints in Von Hippel–Lindau (VHL) Disease Clinical Trials

14. Emerging Therapies

15. Von Hippel–Lindau Disease: 7 Major Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

 

 

Von Hippel–Lindau Market Report Scope

  • The report covers the descriptive overview of Von Hippel-Lindau (VHL) Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies.
  • Comprehensive insight has been provided into the Von Hippel-Lindau (VHL) Disease epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Von Hippel-Lindau (VHL) Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the historical and forecasted Von Hippel-Lindau (VHL) Disease market is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Von Hippel-Lindau (VHL) Disease market.

 

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Von Hippel-Lindau (VHL) Disease market.
  • To understand the future market competition in the Von Hippel-Lindau (VHL) Disease market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Von Hippel-Lindau (VHL) Disease in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Von Hippel-Lindau (VHL) Disease market.
  • To understand the future market competition in the Von Hippel-Lindau (VHL) Disease market.

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/